News | May 12, 2026
JB Chemicals reports muted Q4 FY26 as integration resets business
The CDMO segment saw a 22% decline in Q4 due to a strong base in the prior year
The CDMO segment saw a 22% decline in Q4 due to a strong base in the prior year
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit
With robust FY26 growth, plans AI-led diagnostics and genomic testing expansion
FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures
Subscribe To Our Newsletter & Stay Updated
